MEDI5752 是一种单价双特异性免疫疗法，具有独特的战略意义，因为它结合了抗程序性细胞死亡 1 和抗细胞毒性 T 淋巴细胞相关蛋白 4 的作用。这是此类分子中的第一个。这种分子的发展非常有趣，通常不会在常规临床肿瘤学期刊中描述，因此失去了即将到来的主题的重要历史片段。到目前为止，仅发布了此类开发的一些第一阶段结果，并且到目前为止还没有完整的报告。这项工作将尝试记录发明和进入 III 期试验时实际发生的事实和一系列事件。© 2024。亚洲妇科肿瘤学会、韩国妇科肿瘤学会和日本妇科肿瘤学会。

MEDI5752 is a monovalent bispecific immunotherapy and is strategically unique as it combines both anti programmed cell death 1 and anti cytotoxic T-lymphocyte-associated protein 4 action. This is one of the first of this kind of molecule. The development of this molecule had been very interesting which is not usually described in regular clinical oncology journals thus losing an important piece of history of an upcoming subject. Only some phase I results in such development is published so far and no full report on this is available till now. This effort will try to record the facts and chain of events which actually occurred in inventing and bringing it in phase III trial.© 2024. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology, and Japan Society of Gynecologic Oncology.